Alzamend neuro announces addition of healthy subjects to ongoing phase iia clinical trial for al001 in alzheimer's subjects

Atlanta--(business wire)---- $acad #al001_mitigates_lithium_toxicities--alzamend neuro announces addition of healthy subjects to ongoing phase iia clinical trial for al001 targeting alzheimer's; pursuing add'l indications
ACAD Ratings Summary
ACAD Quant Ranking